Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|March 15, 2021
- Pharmaceutical Technology-03-15-2021
- Volume 2021 eBook
- Issue 1
FDA 2021 Guidance Agenda Sees Focus on Generics
Author(s)Susan Haigney
The agency’s focus appears to be on generic drugs for the upcoming year.
Advertisement
For the bio/pharmaceutical industry, 2020 was a challenging year, as industry worked to develop and manufacture vaccines and treatments for the COVID-19 pandemic. Despite an increased workload and travel restrictions precipitated by the pandemic, FDA continued to meet goals and approve new drug products. As the effects of the pandemic continued in the first quarter of 2021, FDA’s two bio/pharma sectors, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), have announced their guidance agendas for the year.CDER has plans for new or updated guidance documents in a variety of areas, especially for generic drugs and procedural updates; CBER is focused on tissues and advanced therapies.
About the author
Susan Haigney is managing editor of Pharmaceutical Technology.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 6–9
Citation
When referring to this article, please cite it as S. Haigney, “FDA 2021 Guidance Agenda Sees Focus on Generics," Pharmaceutical Technology Regulatory Sourcebook eBook (March 2021).
Articles in this issue
over 5 years ago
It Takes a Bio/Pharma Villageover 5 years ago
Managing the Risk of Nitrosamine Impuritiesover 5 years ago
Collaborative Efforts Address Key Data Integrity Challengesover 5 years ago
Can FDA Reinvent Inspectionsover 5 years ago
A Real-World Approach to Evaluating Cleanroom Garmentsover 5 years ago
Resources, Guidelines, and Guidance Documents Directoryover 5 years ago
Regulatory and Standard Setting Organizations DirectoryAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Complying with International Pharmacopoeias
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5